Ascendis Pharma A/S
ASND
23 hedge funds and large institutions have $184M invested in Ascendis Pharma A/S in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 10 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
12% less funds holding
Funds holding: 26 → 23 (-3)
18% less capital invested
Capital invested by funds: $223M → $184M (-$39.1M)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$30.3M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$19.3M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$5.36M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.03M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$3.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$26.1M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
-$18.3M |
| 3 |
Lazard Asset Management
New York
|
-$3.58M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.32M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$577K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Lazard Asset Management
New York
| – | -$3.58M | -193,050 | Closed |
|
|
PAMU
27
Pictet Asset Management (UK)
London,
United Kingdom
| – | -$540K | -31,100 | Closed |
|
|
SAM
28
Sectoral Asset Management
Montreal,
Quebec, Canada
| – | -$577K | -31,100 | Closed |
|
|
AA
29
ALPS Advisors
Denver,
Colorado
| – | -$524K | -28,259 | Closed |
|
30
Morgan Stanley
New York
| – | -$478K | -25,759 | Closed |
|
31
UBS Group
Zurich,
Switzerland
| – | -$26K | -1,417 | Closed |
|
32
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$1K | -79 | Closed |
|
33
Citigroup
New York
| – | -$1K | -50 | Closed |
|
ASND Hedge Fund Activity: Q2 2016 in Review
23 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2016, worth a combined $184M — down 18% from $223M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ASND and 7 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 10 added.
The largest buyer was OrbiMed, adding an estimated $30.3M. The largest seller was Visium Asset Management, exiting entirely with an estimated $26.1M sold.
- 23 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2016, down from 26 in Q1 2016.
- Funds reported $184M of Ascendis Pharma A/S stock for Q2 2016, down 18% quarter-over-quarter.
- 7 funds opened new Ascendis Pharma A/S positions in Q2 2016 and 10 closed out, a net change of -3 holders.
- The largest Ascendis Pharma A/S buyer in Q2 2016 was OrbiMed, an estimated $30.3M added.
- The largest Ascendis Pharma A/S seller in Q2 2016 was Visium Asset Management, an estimated $26.1M sold.
Based on aggregated 13F filings for Q2 2016.